Avencell

Next generation immunotherapies for hard-to-treat cancers.

Avencell is a biotech company in Watertown, United States, founded in 2021. It has raised $152.0M across 5 rounds, most recently a $40.0M Grant in June 2025.

Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$152.0M
Last Round
$40.0M GrantJun 2025
Rounds
5

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 5 funding rounds and 6 investors for this company. to use credits for reveals, or explore the API.

About

AvenCell Therapeutics is a clinical-stage biopharma developing next-generation allogeneic and switchable CAR-T cell therapies for hard-to-treat cancers. Their proprietary platforms enable precise targeting, controllability, and safety, overcoming limitations of current immunotherapies. Backed by leading investors, they focus on advancing immunotherapies to improve patient outcomes globally.

Funding History

Data from Indexed.vcUpdated
GrantAMED GrantJun 2025
$40.0M

4 more events

  • Series B20245 investors
  • Seed20212 investors
  • Grant

Funding: Seed through Grant. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Marketing & SEO ×2
  • DevOps ×1
  • Other ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech
Venture RoundTotal funding$884.0MJul 2025
Tessera Therapeutics

Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...

Somerville, United States201–500Biotech
Corporate RoundTotal funding$730.0MDec 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech
Private EquityTotal funding$647.0MFeb 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Avencell on Indexed.vc
<a href="https://indexed.vc/companies/avencell"><img src="https://indexed.vc/api/badge/company/avencell" alt="Avencell on Indexed.vc" width="260" height="76" /></a>